思他宁在合并肝炎后肝硬化的肝癌切除术中的应用.docVIP

思他宁在合并肝炎后肝硬化的肝癌切除术中的应用 　　[摘要] 目的 探讨思他宁在合并肝炎后肝硬化的肝癌切除术中的应用价值。方法 选取该科收治的58例肝硬化并行肝癌切除术的患者随机分组，28例术中至术后72 h持续泵注思他宁治疗（观察组），另30例未用任何生长抑素类药物（对照组），观察围手术期情况。结果 两组患者均无住院期间死亡。观察组的术中出血及肝门阻断例数比对照组显著减少；术后第3天肝酶水平、胸腹水例数、腹腔管留置时间及住院时间均较对照组明显减少。结论 思他宁可明显减少合并肝炎后肝硬化的肝癌切除术中的术中出血，促进肝功能恢复，减少腹水等术后并发症，安全有效，值得临床推广应用。 　　[关键词] 肝细胞癌；肝硬化；生长抑素 　　[中图分类号] R735 [文献标识码] A [文章编号] 1674-0742（2013）07（c）-0088-02 　　The Effect of Somatostatin on Patients with Cirrhosis and Hepatocellular Carcinoma after Hepatectomy 　　CEN Junhua FENG Jutao CHEN Jinsong LI Jun 　　Department of Hepatobiliary Surgery， The 1st Affiliated Hospital of Guangzhou Medical University， Guangdong Province，Guangzhou 510120， China 　　[Abstract] Objective To investigate the Stilamin with hepatitis cirrhosis of liver cancer resection in value. Methods Undergraduate from January 2012 to December parallel treated 58 patients with liver cirrhosis liver cancer resection in patients randomized， 28 cases of surgery to 72 hours after continuous infusion Stilamin treatment（observation group）， and 30 patients did not any the somatostatin drugs （control group）， observed the perioperative period. Results Two groups of patients had died during hospitalization. Blood loss and liver of the observation group， the door blocking the number of cases significantly reduced compared with the control group； 3 days after liver enzyme levels， the number of cases of pleural effusion， abdominal tube indwelling time and length of hospital stay was significantly reduced compared with the control group. Conclusion Think he would rather significantly reduced blood loss in the combined hepatitis， cirrhosis liver cancer resection， and promote liver function and reduce postoperative complications such as ascites， safe and effective， worthy of clinical application. 　　[Key words] Hcc；Cirrhosis； Somatostatin 　　肝癌已成为我国恶性肿瘤第二号杀手，手术切除是目前唯一可能根治肝癌的治疗方法[1]。但我国绝大多数肝癌患者就诊时已属中晚期且多伴有肝炎后肝硬化，故目前肝癌的手术切除率不到20%[2]。为探讨思他宁在合并肝炎后肝硬化的肝癌切除术中的应用价值，本前瞻性随机对照研究通过观察思他宁在2012年1―12月来该院行肝癌切除术的肝